

# Stella Youngeun Ko, PharmD MS

Millbrae, CA 94030 • (773)-896-8966 • [stellako@uw.edu](mailto:stellako@uw.edu) • [www.linkedin.com/in/stellayeko](http://www.linkedin.com/in/stellayeko)

## EDUCATION

---

- Master of Science – Health Economics and Outcomes Research** June 2023  
University of Washington, Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute  
*Thesis: Productivity loss among patients with diabetic macular edema in two eyes: a retrospective commercial claims analysis in the United States*
- Doctor of Pharmacy with Honors** May 2022  
University of North Carolina at Chapel Hill  
*Thesis: Understanding the importance of racial diversity in development and implementation of pharmacogenomic guidelines in kidney transplant patients receiving tacrolimus.*
- Bachelor of Science – Neuroscience** June 2017  
University of California Los Angeles

## PROFESSIONAL EXPERIENCES

---

### **Evidence for Access, Genentech Inc**

*University of Washington & Genentech Post-Doctoral Health Economics and Outcomes Research Fellow*  
July 2022 – Present

- Conduct health economics and outcomes research (HEOR) studies, including economic modeling and analyses, patient-reported outcomes research, and real-world evidence generation in preparation of product launch (Xolair (omalizumab) in food allergy).
- Support health economist leads to develop evidence strategies and tactics for immunology/respiratory and ophthalmology portfolios, in collaboration with cross-functional matrix teams, including Medical Affairs, Government Affairs, Commercial and Product Development, and external stakeholders.
- Develop cost-effectiveness analyses to support potential intervention assessment from the Institute for Clinical and Economic Review (ICER) while engaging with a vendor and key opinion leaders (manuscript in preparation).
- Collaborate with internal data scientists to design and conduct HEOR studies to support value demonstration and evidence generation to support therapeutic access.
- Engage with external customers and therapeutic area experts, including academic researchers, healthcare providers, payers, and professional societies.

### **AESARA, Inc**

*Health Economics & Outcomes Research/Market Access Intern* May 2020 – December 2021

- Develop an educational module on economic modeling to provide information on budget impact model and cost-effectiveness models and how those models are used in AMCP dossier.
- Create a presentation on the process of Health Technology Assessment and Pricing and Reimbursement in different countries (Canada, Australia, Italy, Switzerland, Singapore, and Germany).
- Organize an AMCP dossier for a new drug to be considered on the payer's formulary.
- Create a presentation regarding the new value framework developed by The Professional Society for Health Economics and Outcomes Research (ISPOR) comparing it with the value framework developed by ICER.

### **Drug Information, UNC Health Systems**

*Strategic Sourcing and Shortage Management Extern* August 2021 – August 2021

- Critically evaluated clinical and economical data to create a drug monograph for a new levonorgestrel-releasing intrauterine system, Kyleena, to be considered on Integrated Delivery Network (UNC Health System) formulary by critically evaluating clinical and economic data.
- Created visual comparison that compares between new pneumococcal vaccines and local anesthetics to be approved for P&T Committee in UNC Health Systems.

**Department of Global Health Economics for Pharmacy, UNC Eshelman School of Pharmacy**

*Pharmacoeconomics and Outcomes Research Intern*

January 2019 – April 2021

- Performed systematic literature review and meta-analysis to examine the relationship between cognitive ability and educational outcomes, and between cognitive ability and economic outcomes in low- and middle-income countries.
- Design and execute research independently to quantify the clinical benefits of incorporating pharmacogenomic guidelines in different racial populations receiving tacrolimus by developing a simulated patient population using SAS.

**ORAL PODIUM PRESENTATIONS**

**American Academy of Allergy Asthma & Immunology** 2024

Bird AJ, Wang J, Seetasith A, Garmo V, **Ko S**, Lee I, Wang E, Zhao X, Near A, Gupta S, Fleischer D. Hospitalizations and Emergency Department Visits Before and After Omalizumab Treatment in Patients With Asthma and Food Allergies

**The Association for Research in Vision and Ophthalmology** 2024

Borkar DS, Tabano D, **Ko S**, Leng T, Shaia JK, Myers R, LaPrise A, Ali F, Singh RP. Real-world clinical and anatomical outcomes in patients with diabetic macular edema treated with faricimab: The FARETINA-DME study

**The Association for Research in Vision and Ophthalmology** 2024

Tabano D, **Ko S**, Borkar D, Leng T, Ali F, Shaia JK, Myers R, LaPrise A, Singh RP. Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINA-AMD study

**Real World Data Forum 2023 (Roche Global meeting)** 2023

**Ko S**, Tabano D, Borkar D, Leng T, Shaia JK, Kuo BL, Myers R, LaPrise A, Singh, RP. Early Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema and Neovascular Age-related Macular Degeneration Initiating Faricimab: The FARETINA-DME/AMD Study

**CONFERENCE POSTERS**

**The American Society of Retina Specialists** 2024

Faux N, McAllister M, **Ko S**, Tabano D, Bawa K, Mearns ES, Patel S, Spicer G, Martinez A, Lim J. Assessing the Strength of Clinical Practice Guidelines for Managing Neovascular Age-related Macular Degeneration: A Systematic Literature Review (submitted)

**The American Society of Retina Specialists** 2024

McAllister M, Faux N, **Ko S**, Tabano D, Bawa K, Mearns ES, Patel S, Spicer G, Martinez A, Lim J. Assessing the Strength of Clinical Practice Guidelines for Managing Diabetic Macular Edema: A Systematic Literature Review (submitted)

**The Professional Society for Health Economics and Outcomes Research** 2024

Tabano D, Moustaid FE, Rosettie KL, **Ko S**, Meer E, Brodie F. Economic Benefit of Faricimab Compared to Aflibercept 8mg in Treating Patients with Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the United States (submitted)

**The Professional Society for Health Economics and Outcomes Research** 2023

Stella Ko 2

**Ko S, Bansal A, Veenstra D.** Health State Utility and Quality of Life Measures for Neovascular Age-related Macular Degeneration.

**The Professional Society for Health Economics and Outcomes Research** 2023  
**Ko S, Veenstra D.** The Impact of Different Utility Values on a Cost-effectiveness model in Diabetic Macular Edema

**American Society of Human Genetics 2021** 2021  
**Ko Y, Roberts MC, Seyerle AA.** Understanding the Importance of Racial Diversity in Development and Implementation of Pharmacogenomic Guidelines in Kidney Transplant Patients Receiving Tacrolimus.

#### PUBLICATIONS

---

**Journal of Visual Impairment and Blindness** 2024  
**Ko S, Veenstra D, Tabano D, Bansal A.** Productivity loss among patients with diabetic macular edema in two eyes: a retrospective commercial claims analysis in the United States. *Journal of Visual Impairment and Blindness*. 2024 (submitted)

**World Development** August 2021  
**Ozawa S, Laing SK, Higgins C, Yemeke T, Chong C, Carlson R, Ko Y, Guterman BL, Omer SB.** Educational and Economic Returns to Cognitive Ability in Low- and Middle- Income Countries: A Systematic Review. *World Development*. 2021; (August 13, epub ahead of print).

#### CERTIFICATIONS AND LICENSURES

---

**Pharmacist License** September 2023  
*Washington State Department of Health*  
**Basic Life Support (BLS) for Healthcare Providers** September 2020  
*American Heart Association*  
**Pharmacy Based Immunization Delivery** October 2018  
*American Pharmacists Association*

#### REFERENCES

---

- David Tabano, Principal Health Economist, Genentech, 650-452-3252, [tabanod@gene.com](mailto:tabanod@gene.com)
- Arpamas Seetasith, Senior Health Economist, Genentech, 650-491-4782, [seetasith.arpamas@gene.com](mailto:seetasith.arpamas@gene.com)
- Vincent Garmo, Director, Evidence for Access (E4A), Genentech, 650-922-2342, [garmov@gene.com](mailto:garmov@gene.com)
- David Veenstra, Professor, University of Washington School of Pharmacy, 206-221-6936, [veenstra@uw.edu](mailto:veenstra@uw.edu)
- Aasthaa Bansal, Associate Processor, University of Washington School of Pharmacy, 206-685-9658, [abansal@uw.edu](mailto:abansal@uw.edu)